In the joint organization of Paroco medical equipment doo Novi Sad and Getinge Group, on Friday, January 24, 2025, education and commissioning of the first Fluobeam LM device on the territory of the Republic of Serbia was held at the Institute of Oncology and Radiology of Serbia in Belgrade.
FLUOBEAM LM represents inovative technology manufactured by Getinge group and it is intended to provide an improved approach to surgery, combining near-infrared (NIR) technology and indocyanine green (ICG), creating real-time fluorescence imaging of tissue during surgical procedures. After intravenous or local administration of ICG, FLUOBEAM LM enables unobstructed visualization of blood vessels, tumor borders, sentinel lymph node biopsy, blood flow and tissue perfusion, organ transplantation, and assistance in plastic and reconstructive surgery procedures.
Mr. Théo Serranelli, Clinical Application specialist, Fluorescence Imaging, Getinge Group, responsible for teaching and supporting doctors in the operating room, held a training in the form of presenting the clinical and technological aspects of the successful treatment of various indicated patient conditions using the Fluobeam.
The training was interactive and divided into two segments – theoretical and practical: a presentation of the technical capabilities of the device with examples from practice, followed by procedures in clinically controlled conditions:
Three axillary lymph node biopsies (sentinel lymph node) – This procedure is used to evaluate the presence of cancer metastases in the lymph nodes under the armpit, thus helping to determine further therapeutic steps.
Single illumination and tissue vascularization during breast reconstruction – This technique is used to visualize blood vessels and ensure good blood flow in the tissue used for breast reconstruction, thereby improving the success of the transplant and reducing the risk of necrosis.
We would like to take this opportunity to thank the IORS team for their hospitality and the opportunity to present this technology. We believe that in the future it will significantly contribute to the improvement of the treatment of patients in serious conditions, providing them with better chances for recovery and a better quality of life.
